Skip to main content

Table 3 24-Month Cost-Effectiveness Ratios

From: The effect of medical innovation on the cost-effectiveness of Covid 19-related policies in the United States using a SIR model

  

Do Nothing

Hospital Improvements Only

NMIs Only

Vaccines Only

NMIs + Hospital Improvements

NMIs + Vaccines

Hospital Improvements + Vaccines

NMIs + Hospital Improvements + Vaccines

Total Cost

$559B

$567B

$2.39 T

$607B

$2.39 T

$2.44 T

$615B

$2.45 T

QALYs Lost

10.27 m

6.44 m

11.88 m

8.89 m

5.62 m

9.46 m

6.72 m

5.89 m

Compared to “Do Nothing”

Incremental Cost

Reference

$8B

$1,831B

$48B

$1,839B

$1,881B

$56B

$1,882B

Incremental QALYs gained

Reference

3.8 m

-1.61 m

1.4 m

4.7 m

0.8 m

3.6 m

4.4 m

Cost per QALY Gained

$2,089

Dom

$34,777

$391,277

$2,351,250

$15,773

$427,727

Compared to “Hospital therapeutics and Care Improvements Only”

Incremental Cost

Reference

$1,823 T

$40.0B

$1,831B

$1,873B

$56B

$1,874B

Incremental QALYs Gained

Reference

-5.4 m

-2.5 m

-280 k

-3.0 m

820 k

550 k

Cost per QALY Gained

Dom

Dom

Dom

Dom

$58,528

$3.4 m

  1. Dom Dominated. Table shows the Incremental Cost Effectiveness Ratio (ICER) based on a “Do Nothing” reference category and Hospital Therapeutics and Care Improvements alone. Dominated categories have both higher QALY losses and higher costs